Alogliptin showed only moderate efficacy against NAFLD (as measured based on the NAFIC score—NASH, ferritin, insulin, and collagen 7S score) over a 12-month treatment period in patients with DMT2 and NAFLD [71]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.